<DOC>
	<DOCNO>NCT00221650</DOCNO>
	<brief_summary>Combination PEG interferon ribavirin standard treatment chronic hepatitis C. Efficacy treatment never evaluate HCV-HIV infected patient , previously treat first line anti-HCV treatment . The purpose study evaluate combination PEG interferon alfa2a-ribavirin HIV-infected patient chronic hepatitis C pretreated interferon alone interferon combine ribavirin . The patient receive dose 180 µg PEGASYS week 800 1200 mg/day ribavirin ( accord weight ) 48 week . Primary outcome study sustain virological response , define undetectable HCV RNA level 24 week end anti-HCV treatment .</brief_summary>
	<brief_title>Treatment Chronic Hepatitis C With PEG Interferon alfa2a Ribavirin HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Chronic hepatitis C : Detectable HCV RNA , Previously treat interferon interferon combine ribavirin , Elevated ALT level HIV infection ( CD4 &gt; 250/µL , HIV RNA &lt; 10 000 copies/ml ) treat antiretroviral therapy Signed informed consent Chronic hepatitis B Alcohol consumption &gt; 40g/day Evidence decompensated liver disease Hepatocellular carcinoma Other relevant disorder : organ transplantation , psychiatric cardiovascular disease , poorly control diabetes , seizure disorder , hemoglobinopathy , autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>HCV infection</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Treatment Failure</keyword>
	<keyword>PEG interferon</keyword>
	<keyword>Interferons/therapeutic use</keyword>
	<keyword>Interferon Alfa-2a/adverse effect</keyword>
	<keyword>Ribavirin/therapeutic use</keyword>
	<keyword>Ribavirin/adverse effect</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>